Insightful Analysis on Investing in ILMN – What You Need to Know

By Tamara Parker • Wednesday, December 11 10:13 • Permanent Link

Large-cap Health Care company Illumina has moved -1.7% so far today on a volume of 314,734, compared to its average of 1,905,092. In contrast, the S&P 500 index moved 1.0%.

Illumina trades -11.25% away from its average analyst target price of $164.52 per share. The 25 analysts following the stock have set target prices ranging from $120.0 to $252.0, and on average have given Illumina a rating of buy.

Anyone interested in buying ILMN should be aware of the facts below:

Illumina has moved 20.5% over the last year, and the S&P 500 logged a change of 28.2%
Based on its trailing earnings per share of -9.97, Illumina has a trailing 12 month Price to Earnings (P/E) ratio of -14.6 while the S&P 500 average is 29.3
ILMN has a forward P/E ratio of 33.0 based on its forward 12 month price to earnings (EPS) of $4.42 per share
Its Price to Book (P/B) ratio is 10.86 compared to its sector average of 3.53
Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally.
Based in San Diego, the company has 10,590 full time employees and a market cap of $23.16 Billion.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.